Basic Information
| LncRNA/CircRNA Name | HAS2-AS1 |
| Synonyms | hyaluronan synthase 2 antisense 1 |
| Region | GRCh38_8:121639293-121644693 |
| Ensemble | ENSG00000248690 |
| Refseq | NR_002835 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot, RIP etc |
| Sample | NSCLC and their adjacent normal tissues, cell lines (A549, H1299, SK-MES-1, H460, NHBE) |
| Expression Pattern | up-regulated |
| Function Description | In the NSCLC tissue and cells, HAS2-AS1 was found to be up-regulated, which, in turn, indicated the poor prognosis of NSCLC patients. Functional experiments illustrated that HAS2-AS1 promoted the proliferation, invasion and gefitinib chemotherapy resistance of NSCLC cells. In vivo, HAS2-AS1 knockdown suppressed the tumor growth. Mechanically, HAS2-AS1 recruited the lysine-specific demethylase 1 (LSD1) to the EphB3 promoter region to inhibit its transcription. |
| Pubmed ID | 32269726 |
| Year | 2020 |
| Title | Long Noncoding RNA HAS2-AS1 Accelerates Non-Small Cell Lung Cancer Chemotherapy Resistance by Targeting LSD1/EphB3 Pathway |
External Links
| Links for HAS2-AS1 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |